J&J to resume COVID-19 vaccine shipments to EU, with a warning ‘very rare’ adverse events

Shares of Johnson & Johnson jumped 2.6% toward a 12-week high in midday trading Tuesday, after the drug maker said it will resume shipments of its COVID-19 vaccine in Europe, after the European Medicines Agency said a warning about potential rare blood clots should be added. J&J said it will update its COVID-19 vaccine summary of product characteristics to include information on “the diagnosis and management of this very rare adverse event,” after which shipment of the vaccine will resume to the European Union, Norway and Iceland. “We appreciate the rigorous review of the PRAC [EMA’s Pharmacovigilance Risk Assessment Committee] and share the goal of raising awareness of the signs and symptoms of this very rare event to ensure the correct diagnosis and appropriate treatment,” said J&J Chief Scientific Officer Paul Stoffels. “We strongly believe in the positive benefits of our single-shot, easily transportable COVID-19 vaccine to help protect the health of people everywhere and reach communities in need globally.” J&J’s stock, which is on track for the highest close since Jan. 28, has rallied 10.1% year to date, while the Dow Jones Industrial Average has advanced 10.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.